Althea Technologies & Profectus BioSciences Sign Manufacturing Agreement
Althea Technologies, Inc. and Profectus BioSciences Inc. recently announced the signing of a manufacturing supply agreement for plasmid DNA production. Under the agreement, Althea will provide gram-scale quantities of cGMP manufactured plasmid DNA expressing IL-12 to assist Profectus Biosciences’ ongoing DNA vaccine development efforts, which are supported by a contract from the National Institutes of Health. IL-12 helps prompt an immune response once the DNA enters a cell, which is part of Profectus Biosciences’ technology platform designed to overcome the poor delivery and immunogenicity of many DNA vaccines.
“Profectus is very pleased to establish this partnership with Althea for the production of the clinical grade plasmids for our DNA vaccine programs,” said John Eldridge, Chief Scientific Officer of Profectus BioSciences. “Althea provides an unmatched combination of state-of-the-art facilities and expertise in this area, and we anticipate a long and productive association.”
“We are delighted to be awarded this contract; this project has tremendous potential for treating some of the world’s most devastating and challenging diseases” added Rick Hancock, President and CEO of Althea Technologies. “By establishing this partnership, Althea will be able to leverage our plasmid manufacturing expertise to help advance this DNA vaccines program through the clinic and to the patients who need it.”
Althea Technologies is a fully integrated, contract development and manufacturing organization located in San Diego, CA, providing clinical and commercial product development services. For more information, visit www.altheatech.com.
Profectus BioSciences, Inc. is a technology based vaccine company devoted to the treatment and prevention of infectious diseases and related cancers, with the goal of reducing morbidity and mortality. For more information, visit www.profectusbiosciences.com.
Total Page Views: 1327
